Orientações odontológicas aos pacientes submetidos à quimioterapia antineoplásica

  • Fernanda Angelio da Costa Universidade Estadual de Maringá
  • Mailon Cury Carneiro
  • Erica Ayumi Hoshino
  • Elen de Souza Toletino
  • Mariliani Chicarelli da Silva
  • Nelí Pieralisi
Palavras-chave: Quimioterapia, Efeitos adversos, Câncer de cabeça e pescoço

Resumo

Objetivo: este trabalho propõe condutas bucais aos pacientes com indicação quimioterápica, a partir de uma revisão de literatura, visto que o paciente é pouco orientado em muitos casos. Material e métodos: a busca foi realizada a partir da base de dados PubMed/Medline. Apenas estudos observacionais e revisões da literatura, em inglês, espanhol e português, publicados entre 2001 e 2019, que abordassem o tratamento antineoplásico e apresentassem complicações bucais foram incluídos. Resultados: doze artigos preencheram os critérios de inclusão. Notou-se que a maioria dos efeitos adversos cessam ao fim da quimioterapia. As principais alterações bucais observadas foram mucosite, disgeusia, xerostomia e candidose. Diversas alternativas terapêuticas se mostram eficazes, sendo fundamental individualizar o paciente e propor a melhor opção para o quadro apresentado. Considerações finais: a participação do cirurgião-dentista na equipe oncológica é extremamente importante, realizando intervenções odontológicas e orientando aos pacientes, colaborando para uma melhor qualidade de vida e contribuindo significativamente no prognóstico da doença.

Downloads

Não há dados estatísticos.

Referências

1. Osterne RLV, Brito RGM, Nogueira RLM, Soares ECS, Alves
APNN, Moura JFB, et al. Saúde bucal em pacientes portadores
de neoplasias malignas: estudo clínico-epidemiológico e
análise de necessidades odontológicas de 421 pacientes. Rev
Bras Cancerol. 2008;54(3):221–6.
2. Volpato LER, Silva TC, Oliveira TM, Sakai VT, Machado
MAAM. Radiation therapy and chemotherapy-induced oral
mucositis. Braz J Otorhinolaryngol. 2007;73(4):562–8.
3. Almeida VL, Leitão A, Reina LCB, Montanari CA, Donnici
CL. Câncer e agentes antineoplásicos ciclo-celular específicos
e ciclo-celular não específicos que interagem com o DNA:
uma introdução. Quim Nov. 2005;28(1):118–29.
4. Zeller JL. High suicide risk found for patients with head and
neck cancer. JAMA. 2006;296(14):1716–7.
5. Poulopoulos A, Papadopoulos P, Andreadis D. Chemotherapy:
oral side effects and dental interventions. A review of the
literature. Stomatol Dis Sci. 2017;1(2):35–9.
6. Hespanhol FL, Tinoco EMB, Teixeira HGC, Falabella MEV,
Assis NMSP. Manifestações bucais em pacientes submetidos
à quimioterapia. Cien Saude Colet. 2010;15(1):1085–94.
7. López BC, Esteve CG, Pérez MGS. Dental treatment considerations
in the chemotherapy patient. J Clin Exp Dent.
2011;3(1):31–42.
8. Brennan MT, Hasséus B, Hovan AJ, Raber-Durlacher JE,
Blijlevens NMA, Huysmans MC, et al. Impact of oral side
effects from conditioning therapy before hematopoietic stem
cell transplantation: protocol for a multicenter study. J Med
Internet Res. 2018;7(4):1–8.
9. Alvarado Y, Bellm LA, Giles FJ. Oral mucositis: Time for
more studies. Hematology. 2002;7(5):281–9.
10. Campos MIC, Campos CN, Aarestrup FM, Aarestrup BJV.
Oral mucositis in cancer treatment: natural history, prevention
and treatment. Mol Clin Oncol. 2014;2(3):337–40.
11. Eduardo FDP, Bezinelli LM, De Carvalho DLC, Lopes
RMDG, Fernandes JF, Brumatti M, et al. Oral mucositis
in pediatric patients undergoing hematopoietic stem cell
transplantation: clinical outcomes in a context of specialized
oral care using low-level laser therapy. Pediatr Transplant.
2015;19(3):316–25.
12. Hayashi H, Kobayashi R, Suzuki A, Yamada Y, Ishida M,
Shakui T, et al. Preparation and clinical evaluation of a novel
lozenge containing polaprezinc, a zinc-L-carnosine, for
prevention of oral mucositis in patients with hematological
cancer who received high-dose chemotherapy. Med Oncol.
2016;33(8):1–7.
13. Chaveli-López B, Bagán-Sebastián JV. Treatment of
oral mucositis due to chemotherapy. J Clin Exp Dent.
2016;8(2):201–9.
14. Carneiro-Neto JN, De-Menezes JDS, Moura LB, Massucato
EMS, De-Andrade CR. Protocols for management of oral
complications of chemotherapy and/or radiotherapy for oral
cancer: systematic review and meta-analysis current. Med
Oral Patol Oral Cir Bucal. 2017;22(1):15–23.
15. Cheng Y, Qin SK, Chen YP, Dong lH, Sun XD, Yu SY, et
al. Local analgesic effect of a bioadhesive barrier-forming
oral liquid in cancer patients with oral mucositis caused by
chemotherapy and/or radiotherapy: a randomized multicenter,
single-use, positive-controlled, open-label study. Onco
Targets Ther [Internet]. 2018;11:8555–64. Available from:
https://www.dovepress.com/local-analgesic-effect-of-a-bioadhesive-
barrier-forming-oral-liquid-in-peer-reviewed-article-
OTT
RFO UPF, Passo Fundo, v. 24, n. 3, p. 469-476, set./dez. 2019 475
16. Epstein JB, Thariat J, Bensadoun R-J, Barasch A, Murphy
BA, Kolnick L, et al. Oral complications of cancer and cancer
therapy. A Cancer J Clin. 2012;00(0):1–22.
17. Gil-Montoya JA, Silvestre FJ, Barrios R, Silvestre-Rangil
J. Treatment of xerostomia and hyposalivation in the elderly:
a systematic review. Med Oral Patol Oral Cir Bucal.
2016;21(3):355–66.
18. Chaveli-López B. Oral toxicity produced by chemotherapy: a
systematic review. J Clin Exp Dent. 2014;6(1):81–90.
19. Cinausero M, Aprile G, Ermacora P, Basile D, Vitale MG,
Fanotto V, et al. New frontiers in the pathobiology and treatment
of cancer regimen-related mucosal injury. Front Pharmacol.
2017;8:1–16.
20. Lalla RV, Bowen J, Barasch A, Elting L, Epstein J, Keefe
DM, et al. MASCC/ISOO clinical practice guidelines for the
management of mucositis secondary to cancer therapy. Cancer.
2014;120(10):1453–61.
21. Biron P, Sebban C, Gourmet R, Chvetzoff G, Philip I, Blay
JY. Research controversies in management of oral mucositis.
Support Care Cancer. 2000;8(1):68–71.
22. Trotti A, Bellm LA, Epstein JB, Frame D, Fuchs HJ, Gwede
CK, et al. Mucositis incidence, severity and associated outcomes
in patients with head and neck cancer receiving radiotherapy
with or without chemotherapy: a systematic literature
review. Radiother Oncol. 2003;66(3):253–62.
23. Sonis ST, Elting LS, Keefe D, Peterson DE, Schubert M,
Hauer-Jensen M, et al. Perspectives on cancer therapy-induced
mucosal injury. Cancer. 2004;100(9):1995–2025.
24. Rubenstein EB, Peterson DE, Schubert M, Keefe D, McGuire
D. Clinical practice guidelines for the prevention and treatment
of cancer therapy–induced oral and gastrointestinal
mucositis. Cancer. 2004;100(9):2026–46.
25. Stiff P. Mucositis associated with stem cell transplantation:
current status and innovative approaches to management.
Bone Marrow Transplant. 2001;27(2):3–11.
26. De Souza CA, Santini G, Marino C, Nati S, Congiu AM, Vigorito
AC, et al. Amifostine (WR-2721), a cytoprotective agent
during high-dose cyclophosphamide treatment of non-Hodgkin’s
lymphomas: a phase II study. Brazilian J Med Biol Res.
2000;33(7):791–8.
27. Fahlke J, Ridwelski K, Lippert H. High-dose therapy with
combined 5-fluorouracil and folinic acid with and without
amifostine in the treatment of patients with metastatic colorectal
carcinoma. Int J Color Dis. 1999;14(2):128–30.
28. Kostler WJ, Hejna M, Wenzel C, Zielinski CC. Oral mucositis
complicating chemotherapy and/or radiotherapy:
options for prevention and treatment. CA Cancer J Clin.
2001;51(5):290–315.
29. Rades D, Fehlauer F, Bajrovic A, Mahlmann B, Richter E,
Alberti W. Serious adverse effects of amifostine during radiotherapy
in head and neck cancer patients. Radiother Oncol.
2004;70(3):261–4.
30. Capelli D, Santini G, De Souza C, Poloni A, Marino G, Montanari
M, et al. Amifostine can reduce mucosal damage after
high-dose melphalan conditioning for peripheral blood progenitor
cell autotransplant: a retrospective study. Br J Haematol.
2000;110(2):300–7.
31. Allison RR, Ambrad AA, Arshoun Y, Carmel RJ, Ciuba DF,
Feldman E, et al. Multi-institutional, randomized, double-
blind, placebo-controlled trial to assess the efficacy of a
mucoadhesive hydrogel (MuGard) in mitigating oral mucositis
symptoms in patients being treated with chemoradiation
therapy for cancers of the head and neck. Cancer.
2014;120(9):1433–40.
32. Lanzós I, Herrera D, Santos S, O’Connor A, Peña C, Lanzós
E, et al. Mucositis in irradiated cancer patients: effects of
an antiseptic mouthrinse. Med Oral Patol Oral Cir Bucal.
2010;15(5):732–8.
33. Hadjieva T, Cavallin-Ståhl E, Linden M, Tiberg F. Treatment
of oral mucositis pain following radiation therapy for head-
-and-neck cancer using a bioadhesive barrier-forming lipid
solution. Support Care Cancer. 2014;22(6):1557–62.
34. Raber-Durlacher JE, Von Bültzingslöwen I, Logan RM,
Bowen J, Al-Azri AR, Everaus H, et al. Systematic review
of cytokines and growth factors for the management of
oral mucositis in cancer patients. Support Care Cancer.
2013;21(1):343–55.
35. Zecha JAEM, Raber-Durlacher JE, Nair RG, Epstein JB,
Sonis ST, Elad S, et al. Low level laser therapy/photobiomodulation
in the management of side effects of chemoradiation
therapy in head and neck cancer: part 1: mechanisms of
action, dosimetric, and safety considerations. Support Care
Cancer. 2016;24(6):2781–92.
36. Carvalho PAG, Jaguar GC, Pellizzon AC, Prado JD, Lopes
RN, Alves FA. Evaluation of low-level laser therapy in the
prevention and treatment of radiation-induced mucositis: A
double-blind randomized study in head and neck cancer patients.
Oral Oncol. 2011;47(12):1176–81.
37. Imai H, Soeda H, Komine K, Otsuka K, Shibata H. Preliminary
estimation of the prevalence of chemotherapy-induced
dysgeusia in Japanese patients with cancer. BMC Palliat
Care. 2013;12(1):1–5.
38. Cassolato SF, Turnbull RS. Xerostomia: clinical aspects and
treatment. Gerodontology. 2003;20(2):64–77.
39. Friedman PK, Isfeld D. Xerostomia: the “invisible” oral
health condition. Today’s FDA. 2010;22(1):61–3.
40. Atkinson JC, Baum BJ. Salivary enhancement: current
status and future therapies. J Dent Educ [Internet].
2001;65(10):1096–101. Available from: http://www.ncbi.nlm.
nih.gov/pubmed/11699983.
41. Chambers MS, Posner M, Jones CU, Biel MA, Hodge KM,
Vitti R, et al. Cevimeline for the treatment of postirradiation
xerostomia in patients with head and neck cancer. Int J Radiat
Oncol Biol Phys. 2007;68(4):1102–9.
42. Epstein JB, Gorsky M, Hancock P, Peters N, Sherlock CH.
The prevalence of herpes simplex virus shedding and infection
in the oral cavity of seropositive patients undergoing
head and neck radiation therapy. Oral Surg Oral Med Oral
Pathol Oral Radiol Endod. 2002;94(6):712–6.
43. McCaul LK. Oral and dental management for head and neck
cancer patients treated by chemotherapy and radiotherapy.
Dent Updat. 2012;39(2):135–40.
44. Hong CHL, Napeñas JJ, Hodgson BD, Stokman MA, Mathers-
Stauffer V, Elting LS, et al. A systematic review of dental
disease in patients undergoing cancer therapy. Support
Care Cancer. 2010;18(8):1007–21.
45. 45. Duarte BG, Maciel AP, Gonçales ES, Santos PSDS.
Avaliação perioperatória de indivíduos em quimioterapia com
necessidade de intervenção cirúrgica odontológica. Arq Med
Hosp Fac Cienc Med St Casa São Paulo. 2018;63(2):105–9.
Publicado
2020-10-27
Como Citar
da Costa, F., Carneiro, M., Hoshino, E., Toletino, E., da Silva, M., & Pieralisi, N. (2020). Orientações odontológicas aos pacientes submetidos à quimioterapia antineoplásica. Revista Da Faculdade De Odontologia - UPF, 24(3), 469-476. https://doi.org/10.5335/rfo.v24i3.9629
Seção
Artigos